Effects of irbesartan on renal advanced glycation end products and their receptor in rats with early diabetic nephropathy.
- Author:
Hai-bo LONG
1
;
Hong-xin NIU
;
Xiao-yun LI
;
Wei-dong ZHOU
;
Jing-hua HE
;
Juan ZHONG
;
Lian-bo WEI
Author Information
- Publication Type:Journal Article
- MeSH: Angiotensin II Type 1 Receptor Blockers; therapeutic use; Animals; Biphenyl Compounds; therapeutic use; Diabetes Mellitus, Experimental; complications; Diabetic Nephropathies; drug therapy; metabolism; Glycation End Products, Advanced; genetics; metabolism; Kidney; metabolism; Male; RNA, Messenger; genetics; metabolism; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; genetics; metabolism; Tetrazoles; therapeutic use
- From: Journal of Southern Medical University 2009;29(12):2433-2441
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of irbesartan on the renal expressions of advanced glycation end products (AGEs) and their receptor (RAGEs) in rats with early diabetic nephropathy (DN) and the renoprotection mechanism of irbesartan.
METHODSRat DN models established by a single injection of streptozotocin were randomly divided into the model group and irbesartan treatment group. With normal rats as the control, all the rats received daily gavage for 8 weeks. The 24-h urinary protein excretion and contents of AGEs in the serum and kidney tissues were measured. The expressions of RAGEs and RAGEs protein and mRNA in the kidney tissues were detected by immunohistochemistry and reverse transcription-polymerase chain reaction, respectively. The pathological changes of the kidney were also assessed microscopically.
RESULTSIrbesartan significantly reduced the 24-h urinary protein excretion and the contents of AGEs in the serum and kidney tissues of DN rats, resulting also in decreased expressions of RAGEs and RAGEs protein and mRNA levels in the kidney. The treatment obviously alleviated the pathological changes in the kidney of the DN rats.
CONCLUSIONIrbesartan offers renoprotection against DN possibly by reducing the serum and renal contents of AGEs and inhibiting the renal mRNA expressions of RAGEs and RAGEs.
